Back to News
Market Impact: 0.28
Innate Pharma Q2 Earnings Call Highlights
Source: marketbeat.com
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Innate Pharma reported first-half 2026 clinical and business-development progress, including the closing of its strategic Sobi partnership for lacutamab. The company also completed dose-escalation enrollment for IPH4502 and completed enrollment in the PACIFIC-9 Phase III trial of monalizumab. The milestones modestly de-risk its pipeline execution, although no clinical efficacy data or financial terms were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment
IPHA0.62
SOBI0.38
More News
- Pokémon card curbs send shares of Japanese online marketplace Mercari on a bumpy ride
- US to Sell F-35s to Saudi Arabia in $24.3 Billion Deal
- Jensen Huang says Nvidia will sell twice as many chips next year
- Generac shares surge on big Amazon deal. Wall Street thinks the generator stock has more to go
- After being sidelined, Boeing's Starliner to get starring role in NASA's spaceflight plans
- This AI-picked stock jumps 18% on Amazon’s $8 billion power deal